Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference28 articles.
1. United Nations Programme on HIV/AIDS (UNAIDS). Global HIV & AIDS statistics: fact sheet. 2021. https://www.unaids.org/en/resources/fact-sheet. Accessed 6 Aug 2021.
2. World Health Organization (WHO). Paediatric Antiretroviral Drug Optimization (PADO) Meeting 4. 2018. https://www.who.int/groups/antiretroviral-drug-optimization. Accessed 6 Aug 2021.
3. World Health Organization (WHO). Update of recommendations on first- and second-line antiretroviral regimens. 2019. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1. Accessed 6 Aug 2021.
4. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–35.
5. Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;83(3):310–8.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献